本レポートは、2025年のグローバル臨床試験市場の実態と、2026年以降の有望領域・企業・パイプラインを把握するための市場インテリジェンスレポートです。
フェーズI~III/IVの試験を対象に、試験数、成功率、治療領域別動向、主要スポンサー企業、注目疾患、パイプライン医薬品、市場環境変化を包括的に評価しています。
2025年は完了試験数が前年比11%減少した一方で、成功率や主要評価項目達成試験数は増加しており、本レポートではこの状況を「Quality over Quantity(量より質)」と総括しています。
Drew Muscara
Trialtrove Analyst | Citeline
View profile

Trialtrove Analyst | Citeline
Drew currently supports clinical trial intelligence for the cardiometabolic, vaccine, infectious disease, and genitourinary therapy areas at Citeline. He excels in conducting in-depth data analyses for a variety of applications and utilizes these methods in constructing detailed Ask the Analyst responses. Additionally, through his membership on our analyst bench team, Drew has assisted on a variety of bespoke consulting projects to serve clients. Prior to joining Citeline in 2021, he also conducted research in immunology, lupus, and cell apoptosis. The study focused on determining relative gene expression in cell culture derived from animals that had contracted lupus.
Alexander Noll
Trialtrove Analyst | Citeline
View profile

Trialtrove Analyst | Citeline
Alexander currently supports clinical trial intelligence for the autoimmune, central nervous system, and ophthalmology therapeutic areas at Citeline. On the analyst bench, he has assisted with projects focused on pipeline analysis/ visualization and the epidemiology of rare diseases. Prior to joining Citeline, he worked at the University of Minnesota, conducting preclinical and clinical research on chronic pain. He has a bachelor’s degree in neuroscience and a master’s degree in pharmacology from the University of Minnesota.